Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Information

In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
					(in thousands)
External costs:
Third-party CRO, CMO and other third-party clinical trial costs (1)	$	22,087	$	22,547	$	42,908	$	42,093
License agreement related payments		—		55,000		4,000		60,000
Other research and development costs		2,001		2,346		4,021		4,513
Internal costs:
Employee related expenses		12,061		12,213		24,839		25,710
Total research and development expenses	$	36,149	$	92,106	$	75,768	$	132,316

(1) Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.